Atrium Therapeutics, Inc. - Common Stock (NQ:RNA)

Top movers in Friday's after hours session ↗

February 27, 2026

Via Chartmill

Performance

52-Week Range 87.9% below 52-week high

8.830

7.4952W Low 73.0652W High

1 Week

7.881W Low 8.771W High

Atrium Therapeutics, Inc. - Common Stock (RNA) traded between $7.49 and $73.06 over the past 52 weeks and last traded at $8.83, 87.9% below its 52-week high. Over the past week it ranged between $7.88 and $8.77.

Past 12 Months

+5.1%

+10.8%

-23.5%

-31.6%

-87.8%

-87.3%

1W +$0.43

1M +$0.86

3M -$2.71

6M -$4.08

YTD -$63.27

1Y -$60.97

RNA was -87.3% over the past year, -31.6% over six months, -87.8% year to date, +5.1% in the last week.

12 Months vs Market

RNA

-87.3%

DIA

+11.6%

SPY

+12.3%

QQQ

+9.6%

IWM

+15.7%

Over the past 12 months RNA returned -87.3% versus DIA (Dow) +11.6%, SPY (S&P 500) +12.3%, QQQ (Nasdaq 100) +9.6% and IWM (Russell 2000) +15.7%.

Volume & Liquidity 0.03× 3-mo avg

Today 8,943 3-mo avg 303.1K

341.4K

260.4K

303.1K

253.9K

YTD

761.5K

1.1M

RNA most recently traded 8,943 shares against a 3-month average daily volume of 303.1K.

More News

The Era of the Titans: Q4 2025 Mega-Deal Surge and the 2026 Economic Map

February 06, 2026

Halper Sadeh LLC Encourages TWO, RNA, CVBF, TBN Shareholders to Contact the Firm to Discuss Their Rights

January 31, 2026

From Halper Sadeh LLC

The Biotech Renaissance: Scientific Breakthroughs and M&A Frenzy Spark a New Bull Market

January 22, 2026

Biotech’s Resurgence: How a Year-End Rally and M&A Frenzy Set the Stage for 2026

December 31, 2025

Biopharma’s Year-End Rollercoaster: Mereo Plummets 90% as BioMarin Seals $4.8 Billion Amicus Deal

December 29, 2025

The Biotech Renaissance: Innovation and M&A Frenzy Spark a Historic Year-End Rally

December 22, 2025

This Biotech Fund Just Dumped $14.8 Million in MBX Biosciences — Right Before Key 2026 Milestones ↗

December 03, 2025

Biotech Fund Reveals $15 Million MoonLake Exit After Stock’s 90% Crash ↗

November 28, 2025

Biotech Fund Reveals $15 Million MoonLake Exit After Stock’s 90% Crash ↗

November 27, 2025

This Biotech Fund Just Dumped $14.8 Million in MBX Biosciences — Right Before Key 2026 Milestones ↗

November 27, 2025

Biotech Fund Dumps $12.3 Million in Crinetics Stock as Shares Remain 19% Lower on the Year ↗

November 27, 2025

Halper Sadeh LLC Encourages WTRG, RNA, TCBX Shareholders to Contact the Firm to Discuss Their Rights

November 22, 2025

From Halper Sadeh LLC

Here's How Much $100 Invested In Avidity Biosciences 5 Years Ago Would Be Worth Today ↗

Novartis Projects Faster Growth Through 2030 After Raising Drug Forecasts ↗

November 20, 2025

Via Benzinga

November 19, 2025

Via Benzinga

Looking Into Avidity Biosciences Inc's Recent Short Interest ↗

November 19, 2025

Via Benzinga

Biopharma Boom: M&A Frenzy, AI Revolution, and GLP-1 Gold Rush Drive Robust Growth in 2025

November 14, 2025

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Essential Utilities, Inc. (NYSE – WTRG), Cadence Bank (NYSE – CADE), Avidity Biosciences, Inc. (Nasdaq – RNA), Plymouth Industrial REIT, Inc. (NYSE – PLYM)

November 06, 2025

From Brodsky & Smith LLC

Here's Why Avidity Biosciences Stock Soared This Week (There's More to the Deal Than You Might Think) ↗

October 31, 2025

RNA Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of Avidity Biosciences, Inc. is Fair to Shareholders

Unusual volume stocks in Thursday's session ↗

October 30, 2025

Via Chartmill

$1000 Invested In Avidity Biosciences 5 Years Ago Would Be Worth This Much Today ↗

October 29, 2025

Via Benzinga

October 28, 2025

From Halper Sadeh LLC